Johnson & Johnson completes divestiture of LifeScan to Platinum Equity

Johnson & Johnson announced it has completed the divestiture of its LifeScan diabetes product line to Platinum Equity for $2.1 billion.

J&J said it will continue to serve the diabetes market through its medical device, pharmaceuticals and consumer businesses.

The transaction will be discussed, J&J said, during its earning call on Oct. 16.

Read more from ROI-NJ: